Roxolid® is a metal alloy composed of ~15 % zirconium and ~85 % titanium and has been specifically designed for the use in dental implantology.Titanium-zirconium alloys are stronger than pure titanium 1-3 and have excellent osseointegration properties. Compared to Titanium, Zirconium and Chromium, Roxolid® has the highest biocompatibility score. This combination of properties is unique in the market – and various published clinical studies have documented the successful use of Roxolid® Implants in numerous clinical indications.

Roxolid® builds confidence

Roxolid® splinted with Titanium implants

Study goal: Evaluation of long-term results with 22 patients treated with a Straumann® Standard Plus RN 3.3 mm Roxolid® SLActive® implant splinted to at least one supporting 4.1 or 4.8 mm Titanium ­SLActive® implant in partially edentulous patients.^1,2

Findings: 20 out of 22 patients could be successfully treated (1 did not complete assessment, 1 underwent early loss caused by infection of adjacent tooth).

Roxolid® is as good as titanium

Performance of small-diameter implants made of Roxolid®

Study goal: A randomized, controlled and double-blind multi-center study to evaluate the long-term results of small diameter implants made from Roxolid®, a heads-to-heads comparison to titanium opposites.

Findings: Small diameter implants made of Roxolid® showed high survival (98.7 % after one year, 97.3 % in 3 years) and success rates³. The 12-month results could be maintained over time. In terms of crestal bone change, bleeding and plaque, small diameter implants made of Roxolid® showed no difference to ­titanium implants⁴.

Narrow is the preference

Roxolid®/narrow vs. Titanium/regular

Study goal: Comparison of Straumann® implants made of Roxolid® with narrow diameter versus titanium implants with regular diameter for anterior and premolar single crowns.

Findings: In terms of success rate (100 %) and crestal bone change (no difference), implants from Roxolid® with 3.3 mm diameter are as successful as implants with 4.1 mm^5,6 with reduced chair time and a clear surgeon preference⁶.

Roxolid® is successful in a variety of indications

Roxolid® implants put to the test of daily practice

Study goal: A non-interventional study to evaluate the success and survival rates of implants made from Roxolid® in different indications and health conditions under daily practice conditions.

Findings: Roxolid® implants provide high success and survival rates in various indications and under daily practice conditions. In 54,2 % of the cases, an augmentation could be avoided due to the availability of a Roxolid® implant with a small diameter of 3,3 mm.

Summary: Roxolid® sets new standards in less invasive placement

Different 3-years data from clinical studies confirm that Roxolid® implants are a reliable option for more treatment options and less invasive procedures, setting new standards in less invasive implant placement.

• In terms of material properties, ­Roxolid® behaves like Titanium, but offers key advantages during the surgical procedure.
• Roxolid® is a safe option in load-bearing indications, where implants of reduced diameter are needed due to limited bone availability.
• The now clinically proven advantages offered by Roxolid® can lead to an increased acceptance of implant therapy from clinicians, referrers and patients.